Stage III Lung Cancer: Heidi's Patient Story

Patient Info: Heidi Nafman-Onda, Female, 50s | Stage III

As of November 2021, this caregiver-focused segment centered on Heidi’s Stage IIIA lung cancer diagnosis and Pierre’s advocacy; treatment details and current disease response were not reported.

The Patient StoryRead more →

Stage III Lung Adenocarcinoma: Heidi's Patient Story

Patient Info: Heidi Nafman-Onda, Female, 50s | Stage III

As of November 2021, Heidi was about 3 years out from a Stage IIIA adenocarcinoma lung cancer diagnosis and described living a high-quality life, but treatment details and remission/NED status were not reported.

The Patient StoryRead more →

Strong Response to Pembrolizumab-Based Therapy for Pleomorphic Lung Cancer

Patient Info: Anonymized, Male, 60s | Stage III

Biomarkers: EGFR-negative; ALK-negative; ROS1-negative; PD-L1 TPS 90%-100%.

A marked response followed four combination cycles, and maintenance pembrolizumab remained ongoing seven months after treatment began.

PubMed CentralRead more →

Lung cancer surgery after a Trousseau syndrome-related stroke

Patient Info: Anonymized, Male, 70+ | Stage III

At 23 months after left pneumonectomy, he had no recurrence and continued outpatient surveillance.

PubMed CentralRead more →

Stage III KRAS Non-Small Cell Lung Cancer: Terri's Survivor Story

Patient Info: Terri Conneran, Female | Stage III

Biomarkers: KRAS-mutated; PD-L1 level reviewed/tested

As of March 2021, Terri had Stage IIIA KRAS-mutated NSCLC with 3 local recurrences treated over time and had again reached no evidence of disease while continuing close surveillance and advocacy through KRAS Kickers.

The Patient StoryRead more →

Lung adenocarcinoma with intestinal pseudo-obstruction and Stauffer syndrome

Patient Info: Anonymized, Male, 50s | Stage III

After three chemotherapy courses, the lung tumor had partially responded, intestinal pseudo-obstruction improved, biliary enzyme levels fell, and he continued follow-up as an outpatient.

PubMed CentralRead more →

Blood Vessel Inflammation After Durvalumab Treatment for Stage III Lung Cancer

Patient Info: Anonymized, Female, 70+ | Stage III

The lung cancer had responded well to chemoradiation and durvalumab, while treatment-related pneumonitis and vasculitis improved with corticosteroids and withdrawal or completion of durvalumab.

PubMed CentralRead more →

Multifocal stage IIIA lung adenocarcinoma responding to nivolumab

Patient Info: Anonymized, Female, 60s | Stage III

Biomarkers: CK7-positive; TTF-1-positive; napsin-A-positive; PD-L1 85% positive.

The biopsied lung nodule nearly resolved after four nivolumab cycles, and the remaining pulmonary nodules were stable at 24 months.

PubMed CentralRead more →

Stage III Non-Small Cell Lung Cancer: Renee's Patient Story

Patient Info: Renee Shine, Female, 60s | Stage III

Renee’s tumor responded to pembrolizumab, and she remained on treatment through the clinical trial while describing herself as thriving.

Stage IIIB Squamous Lung Cancer With Fatal Pembrolizumab Pneumonitis

Patient Info: Anonymized, Female, 60s | Stage III

Biomarkers: PD-L1 60%; EGFR negative

She died from severe treatment-related pneumonitis after declining further immunosuppression.

PubMed CentralRead more →

Stage III Lung Adenocarcinoma Resected After Chemotherapy and Checkpoint Immunotherapy

Patient Info: Anonymized, female, 60s | Stage III

After complete resection, she was alive, disease free and off treatment at postoperative follow-up.

PubMed CentralRead more →

Stage IIIB lung adenocarcinoma with separate papillary renal cell carcinoma: doing well more than 6 years after revised diagnosis

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: Lung tumor: TTF-1-positive; PET-avid. Kidney lesion: PET-negative; later papillary renal cell carcinoma. No lung molecular biomarkers reported.

As of February 2014, she was doing well more than 6 years after the initial diagnosis, after the diagnosis was revised from presumed Stage IV lung cancer to Stage IIIB lung adenocarcinoma plus a separate papillary renal cell carcinoma.

PubMed CentralRead more →

Stage IIIA NSCLC with superior vena cava tumor thrombus: complete response to radiation and erlotinib

Patient Info: Anonymized, Male, 60s | Stage III

Biomarkers: EGFR protein expression positive; EGFR gene mutation not tested because tumor sample was inadequate

Radiation plus erlotinib led to complete response of the primary lung tumor at 6 months, disappearance of the SVC thrombosis at 9 months, and no progression during 45 months of close follow-up on maintenance erlotinib.

PubMed CentralRead more →

Stage IIIA pleomorphic lung cancer treated with surgery, chemotherapy, and radiation

Patient Info: Anonymized, Male, Under 40 | Stage III

Alive 14 months after surgery without evidence of tumor recurrence after complete resection, adjuvant chemotherapy, oral S-1, and radiation.

PubMed CentralRead more →

Stage IIIA squamous NSCLC: complete pathological response after docetaxel and lobectomy

Patient Info: Anonymized, Male, 60s | Stage III

Complete clinical response after 14 cycles of docetaxel was confirmed as a complete pathological response after right lobectomy.

PubMed CentralRead more →